New clinical data showed that enfortumab vedotin (Padcev) combined with pembrolizumab delivered additional positive results as a frontline option in a form of bladder cancer, adding to earlier encouraging readouts for the regimen. Investigators presented the findings as part of an ongoing effort to broaden the combination’s labeled indications. The data reinforce a multi‑modality approach—ADC plus checkpoint inhibitor—in urothelial carcinoma and could accelerate regulatory filings and label expansions if corroborated in larger cohorts or randomized studies. Sponsors are likely to use these results to inform future trial design and market positioning.